Current report 28/2021 – Signing of a letter of intent on commencing cooperation with Tarchomińskie Zakłady Farmaceutyczne S.A.

Date: 06/24/2021- 7:28 pm

Management Board of Celon Pharma S.A. (the "Company") informs that the Company and Tarchomińskie Zakłady Farmaceutyczne S.A. with its registered seat in Warsaw ("TZF") signed a letter of intent on June 24, 2021. The parties have declared that:

- taking into account that the Company has both the competences and the technical capacity to develop innovative pharmaceuticals with potential use in the treatment and prevention of COVID-19, treatment of cancer, neurological diseases, diabetes and other metabolic diseases

and

- taking into account that TZF has commenced implementation of an investment in the form of creating a research and production center for highly-active substances (high-potency active pharmaceutical ingredients, HP-APIs),

in order to take full advantage of the synergy of the teams’ experience and technological advancement of both companies, the Company and TZF declare their intention to start cooperation in the area of development (R&D) and production (fill & finish) of medicinal products based on modern technologies (m-RNA), a platform of HP-API drugs with particular focus on new technologies supporting sterile drug forms in to be used in infectious diseases, oncology and metabolic diseases.

The detailed scope of cooperation is to be specified in the potential cooperation agreement.